Elizabeth C. Mitchell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Elizabeth C. Mitchell has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Anita Krishnan
Division of Cardiology, Children’s National Hospital, Washington, DC 20010, USA
2 shared publications - Audrey Dionne
Boston Children's Hospital
2 shared publications Christine A. Capone
2 shared publications- Dongngan T. Truong
Division of Cardiology, Department of Pediatrics, University of Utah and Primary Children's Hospital, Salt Lake City (D.T.T., C.M.F.).
2 shared publications - Jane W. Newburger
Boston Children's Hospital
2 shared publications - Abena Appiah-Kubi
Department of Pediatric Hematology/Oncology & Cellular Therapy, Northwell Health, New York; and Division of Hematology/Oncology and Cellular Therapy, Cohen Children's Medical Center, New York, United States
1 shared publication
Latest Publications
- 3 September 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (9) , e017620
2D Speckle Tracking Strain Echocardiography in Multisystem Inflammatory Syndrome in Children: A Multicenter Analysis From the MUSIC Study
BACKGROUND: 2D-speckle tracking echocardiography may help detect subclinical ventricular dysfunction, but data in multisystem inflammatory syndrome in children (MIS-C) are scarce. We investigated left ventricular (LV) strain parameters in MIS-C and their association with outcomes. METHODS: We performed an ambi-directional, 32-center cohort study on hospitalized MIS-C patients (March 2020–November 2021) with at least 1 echocardiogram read by the Core Lab. Generalized estimating equation modeling was used to test associations between LV strain and a composite in-hospital adverse cardiovascular outcome (vasoactive support, arrhythmias, cardiac arrest, extracorporeal support, death, or heart transplant). RESULTS: Of 349 patients (median age, 8.7 years [interquartile range, 5.3–12.9]), 35% had decreased LV ejection fraction during hospitalization, and 45% had depressed LV strain (either 4-chamber LV longitudinal strain [4CH-LVLS] or mid-ventricular LV circumferential strain [mid-LVCS]). The worst 4CH-LVLS and mid-LVCS occurred at ≈5 days of illness; 50% of abnormal LV strain normalized within 1 week, and 95% within 50 days. In-hospital adverse outcomes occurred in 35% of patients; these patients were older ( P =0.003) and, at admission, had more likely abnormal troponin ( P P P P =0.015), worse LV ejection fraction ( P P =0.002; mid-LVCS, P =0.001). Covariate-adjusted individual models for each strain parameter showed that 4CH-LVLS (adjusted odds ratio, 1.09 [95% CI, 1.07–1.12]), mid-LVCS (adjusted odds ratio, 1.06 [95% CI, 1.04–1.09]), worst LV strain Z score between 4CH-LVLS and mid-LVCS (adjusted odds ratio, 1.30 [95% CI, 1.21–1.41]), and early diastolic longitudinal strain rate (EDLSR; adjusted odds ratio, 1.68 [95% CI, 1.26–2.23]) at admission were found to be associated with adverse outcomes. CONCLUSIONS: About half of MIS-C patients had abnormal LV strain during hospitalization. 4CH-LVLS, mid-LVCS, the most abnormal strain Z score, and early diastolic longitudinal strain rate at admission were independently associated with in-hospital adverse cardiovascular outcome. These data may help early characterization and prognostication in MIS-C.
- 3 September 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 18 (9) , e017620
2D Speckle Tracking Strain Echocardiography in Multisystem Inflammatory Syndrome in Children: A Multicenter Analysis From the MUSIC Study
BACKGROUND: 2D-speckle tracking echocardiography may help detect subclinical ventricular dysfunction, but data in multisystem inflammatory syndrome in children (MIS-C) are scarce. We investigated left ventricular (LV) strain parameters in MIS-C and their association with outcomes. METHODS: We performed an ambi-directional, 32-center cohort study on hospitalized MIS-C patients (March 2020–November 2021) with at least 1 echocardiogram read by the Core Lab. Generalized estimating equation modeling was used to test associations between LV strain and a composite in-hospital adverse cardiovascular outcome (vasoactive support, arrhythmias, cardiac arrest, extracorporeal support, death, or heart transplant). RESULTS: Of 349 patients (median age, 8.7 years [interquartile range, 5.3–12.9]), 35% had decreased LV ejection fraction during hospitalization, and 45% had depressed LV strain (either 4-chamber LV longitudinal strain [4CH-LVLS] or mid-ventricular LV circumferential strain [mid-LVCS]). The worst 4CH-LVLS and mid-LVCS occurred at ≈5 days of illness; 50% of abnormal LV strain normalized within 1 week, and 95% within 50 days. In-hospital adverse outcomes occurred in 35% of patients; these patients were older ( P =0.003) and, at admission, had more likely abnormal troponin ( P P P P =0.015), worse LV ejection fraction ( P P =0.002; mid-LVCS, P =0.001). Covariate-adjusted individual models for each strain parameter showed that 4CH-LVLS (adjusted odds ratio, 1.09 [95% CI, 1.07–1.12]), mid-LVCS (adjusted odds ratio, 1.06 [95% CI, 1.04–1.09]), worst LV strain Z score between 4CH-LVLS and mid-LVCS (adjusted odds ratio, 1.30 [95% CI, 1.21–1.41]), and early diastolic longitudinal strain rate (EDLSR; adjusted odds ratio, 1.68 [95% CI, 1.26–2.23]) at admission were found to be associated with adverse outcomes. CONCLUSIONS: About half of MIS-C patients had abnormal LV strain during hospitalization. 4CH-LVLS, mid-LVCS, the most abnormal strain Z score, and early diastolic longitudinal strain rate at admission were independently associated with in-hospital adverse cardiovascular outcome. These data may help early characterization and prognostication in MIS-C.
- Open Access
- 31 May 2024
- Published by IntechOpen
Cardiopulmonary Complications of Sickle Cell Disease in Children
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy leading to hemolysis, increased endothelial adhesion, inflammation, and vasculopathy. While most children with SCD have normal pulmonary function, lung capacity and expiratory flows are lower compared to age- and racially matched controls. Airway obstruction dominates in children, with restrictive ventilatory defects becoming more prevalent in adolescents and young adults. Decreased pulmonary function, physician-diagnosed asthma, airway hyperresponsiveness, wheezing, and sleep-disordered breathing are associated with more frequent episodes of acute chest syndrome and vaso-occlusive crisis. Chronic lung disease, thromboembolism, hypoxemia, and sleep-disordered breathing are associated with the development of pulmonary hypertension and ventricular dysfunction which carry significant morbidity and mortality risk in adults. Most treatments for cardiopulmonary complications of SCD are based on guidelines developed for the general population. Although most guidelines do not recommend routine screening of asymptomatic children, patients with cardiopulmonary symptoms should be monitored and treated by subspecialists in a multidisciplinary setting. Disease modifying treatments such as hydroxyurea are attenuating some of the cardiopulmonary complications in SCD. More studies need to be done to assess the effects of newer disease modifying treatments targeting hemolysis and decreasing endothelial adhesion.
- 31 May 2024
- Published by IntechOpen
Open AccessCardiopulmonary Complications of Sickle Cell Disease in Children
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy leading to hemolysis, increased endothelial adhesion, inflammation, and vasculopathy. While most children with SCD have normal pulmonary function, lung capacity and expiratory flows are lower compared to age- and racially matched controls. Airway obstruction dominates in children, with restrictive ventilatory defects becoming more prevalent in adolescents and young adults. Decreased pulmonary function, physician-diagnosed asthma, airway hyperresponsiveness, wheezing, and sleep-disordered breathing are associated with more frequent episodes of acute chest syndrome and vaso-occlusive crisis. Chronic lung disease, thromboembolism, hypoxemia, and sleep-disordered breathing are associated with the development of pulmonary hypertension and ventricular dysfunction which carry significant morbidity and mortality risk in adults. Most treatments for cardiopulmonary complications of SCD are based on guidelines developed for the general population. Although most guidelines do not recommend routine screening of asymptomatic children, patients with cardiopulmonary symptoms should be monitored and treated by subspecialists in a multidisciplinary setting. Disease modifying treatments such as hydroxyurea are attenuating some of the cardiopulmonary complications in SCD. More studies need to be done to assess the effects of newer disease modifying treatments targeting hemolysis and decreasing endothelial adhesion.
- 27 February 2023
- Published by Taylor & Francis
- p. 232-255
Pediatric Issues
A subset of patients report a variety of physical, cognitive, and affective symptoms three months from the onset of acute COVID-19 infection and not explained by an alternative diagnosis, which has been named Long COVID or post-acute sequelae of SARS-CoV-2 (PASC). Residual disease from acute infection such as myocardial and pulmonary fibrosis must also be ruled out as well as other post-COVID conditions including critical illness myopathy and deconditioning. Around 2% of patients with asymptomatic or mild disease experience Long COVID or PASC; however, this condition is reported in up to 30% of patients who are hospitalized or develop multi-system inflammatory syndrome in Children (MIS-C). In this chapter, we review acute manifestations and subsequent complications of acute COVID-19 infection, and existing literature on Long COVID including risk factors and pathophysiology, and provide recommendations for management and follow up. We elaborate further on the most commonly reported cardiopulmonary symptoms of shortness of breath, orthostatic symptoms, and post-exertional malaise or fatigue to include the review of impairment in tests of pulmonary and cardiac function.
- 27 February 2023
- Published by Taylor & Francis
- p. 232-255
Pediatric Issues
A subset of patients report a variety of physical, cognitive, and affective symptoms three months from the onset of acute COVID-19 infection and not explained by an alternative diagnosis, which has been named Long COVID or post-acute sequelae of SARS-CoV-2 (PASC). Residual disease from acute infection such as myocardial and pulmonary fibrosis must also be ruled out as well as other post-COVID conditions including critical illness myopathy and deconditioning. Around 2% of patients with asymptomatic or mild disease experience Long COVID or PASC; however, this condition is reported in up to 30% of patients who are hospitalized or develop multi-system inflammatory syndrome in Children (MIS-C). In this chapter, we review acute manifestations and subsequent complications of acute COVID-19 infection, and existing literature on Long COVID including risk factors and pathophysiology, and provide recommendations for management and follow up. We elaborate further on the most commonly reported cardiopulmonary symptoms of shortness of breath, orthostatic symptoms, and post-exertional malaise or fatigue to include the review of impairment in tests of pulmonary and cardiac function.
- 14 February 2022
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 66
Multisystem inflammatory syndrome in children: Salient echocardiogram findings in the acute phase and longitudinal follow-up
- 14 February 2022
- Published by Elsevier in Progress in Pediatric Cardiology
- Vol. 66
Multisystem inflammatory syndrome in children: Salient echocardiogram findings in the acute phase and longitudinal follow-up
- Top Cited Papers
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 145 (5) , 345-356
Clinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination
Background: Understanding the clinical course and short-term outcomes of suspected myocarditis after the coronavirus disease 2019 (COVID-19) vaccination has important public health implications in the decision to vaccinate youth. Methods: We retrospectively collected data on patients <21 years old presenting before July 4, 2021, with suspected myocarditis within 30 days of COVID-19 vaccination. Lake Louise criteria were used for cardiac MRI findings. Myocarditis cases were classified as confirmed or probable on the basis of the Centers for Disease Control and Prevention definitions. Results: We report on 139 adolescents and young adults with 140 episodes of suspected myocarditis (49 confirmed, 91 probable) at 26 centers. Most patients were male (n=126, 90.6%) and White (n=92, 66.2%); 29 (20.9%) were Hispanic; and the median age was 15.8 years (range, 12.1–20.3; interquartile range [IQR], 14.5–17.0). Suspected myocarditis occurred in 136 patients (97.8%) after the mRNA vaccine, with 131 (94.2%) after the Pfizer-BioNTech vaccine; 128 (91.4%) occurred after the second dose. Symptoms started at a median of 2 days (range, 0–22; IQR, 1–3) after vaccination. The most common symptom was chest pain (99.3%). Patients were treated with nonsteroidal anti-inflammatory drugs (81.3%), intravenous immunoglobulin (21.6%), glucocorticoids (21.6%), colchicine (7.9%), or no anti-inflammatory therapies (8.6%). Twenty-six patients (18.7%) were in the intensive care unit, 2 were treated with inotropic/vasoactive support, and none required extracorporeal membrane oxygenation or died. Median hospital stay was 2 days (range, 0–10; IQR, 2–3). All patients had elevated troponin I (n=111, 8.12 ng/mL; IQR, 3.50–15.90) or T (n=28, 0.61 ng/mL; IQR, 0.25–1.30); 69.8% had abnormal ECGs and arrhythmias (7 with nonsustained ventricular tachycardia); and 18.7% had left ventricular ejection fraction <55% on echocardiogram. Of 97 patients who underwent cardiac MRI at a median 5 days (range, 0–88; IQR, 3–17) from symptom onset, 75 (77.3%) had abnormal findings: 74 (76.3%) had late gadolinium enhancement, 54 (55.7%) had myocardial edema, and 49 (50.5%) met Lake Louise criteria. Among 26 patients with left ventricular ejection fraction <55% on echocardiogram, all with follow-up had normalized function (n=25). Conclusions: Most cases of suspected COVID-19 vaccine myocarditis occurring in persons <21 years have a mild clinical course with rapid resolution of symptoms. Abnormal findings on cardiac MRI were frequent. Future studies should evaluate risk factors, mechanisms, and long-term outcomes.
- 1 February 2022
- Published by Wolters Kluwer Health in Circulation
- Vol. 145 (5) , 345-356
Top Cited PapersClinically Suspected Myocarditis Temporally Related to COVID-19 Vaccination in Adolescents and Young Adults: Suspected Myocarditis After COVID-19 Vaccination
Background: Understanding the clinical course and short-term outcomes of suspected myocarditis after the coronavirus disease 2019 (COVID-19) vaccination has important public health implications in the decision to vaccinate youth. Methods: We retrospectively collected data on patients <21 years old presenting before July 4, 2021, with suspected myocarditis within 30 days of COVID-19 vaccination. Lake Louise criteria were used for cardiac MRI findings. Myocarditis cases were classified as confirmed or probable on the basis of the Centers for Disease Control and Prevention definitions. Results: We report on 139 adolescents and young adults with 140 episodes of suspected myocarditis (49 confirmed, 91 probable) at 26 centers. Most patients were male (n=126, 90.6%) and White (n=92, 66.2%); 29 (20.9%) were Hispanic; and the median age was 15.8 years (range, 12.1–20.3; interquartile range [IQR], 14.5–17.0). Suspected myocarditis occurred in 136 patients (97.8%) after the mRNA vaccine, with 131 (94.2%) after the Pfizer-BioNTech vaccine; 128 (91.4%) occurred after the second dose. Symptoms started at a median of 2 days (range, 0–22; IQR, 1–3) after vaccination. The most common symptom was chest pain (99.3%). Patients were treated with nonsteroidal anti-inflammatory drugs (81.3%), intravenous immunoglobulin (21.6%), glucocorticoids (21.6%), colchicine (7.9%), or no anti-inflammatory therapies (8.6%). Twenty-six patients (18.7%) were in the intensive care unit, 2 were treated with inotropic/vasoactive support, and none required extracorporeal membrane oxygenation or died. Median hospital stay was 2 days (range, 0–10; IQR, 2–3). All patients had elevated troponin I (n=111, 8.12 ng/mL; IQR, 3.50–15.90) or T (n=28, 0.61 ng/mL; IQR, 0.25–1.30); 69.8% had abnormal ECGs and arrhythmias (7 with nonsustained ventricular tachycardia); and 18.7% had left ventricular ejection fraction <55% on echocardiogram. Of 97 patients who underwent cardiac MRI at a median 5 days (range, 0–88; IQR, 3–17) from symptom onset, 75 (77.3%) had abnormal findings: 74 (76.3%) had late gadolinium enhancement, 54 (55.7%) had myocardial edema, and 49 (50.5%) met Lake Louise criteria. Among 26 patients with left ventricular ejection fraction <55% on echocardiogram, all with follow-up had normalized function (n=25). Conclusions: Most cases of suspected COVID-19 vaccine myocarditis occurring in persons <21 years have a mild clinical course with rapid resolution of symptoms. Abnormal findings on cardiac MRI were frequent. Future studies should evaluate risk factors, mechanisms, and long-term outcomes.